DDInter1340 DDInter1281
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may lead to a major life threatening interaction when taken with {v} Neratinib
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may lead to a major life threatening interaction when taken with {v} Neratinib
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Omeprazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Digoxin
Digoxin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may lead to a major life threatening interaction when taken with {v} Erlotinib
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may lead to a major life threatening interaction when taken with {v} Erlotinib
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may lead to a major life threatening interaction when taken with {v} Erlotinib
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Omeprazole {u} (Compound) causes {v} (Side Effect) Infestation NOS
Infestation NOS {u} (Side Effect) is caused by {v} (Compound) Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may lead to a major life threatening interaction when taken with Neratinib
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may lead to a major life threatening interaction when taken with Neratinib
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Omeprazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound) and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may lead to a major life threatening interaction when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may lead to a major life threatening interaction when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may lead to a major life threatening interaction when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Omeprazole (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapatinib (Compound) and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib